| 1 |
Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013[J]. J Natl Cancer Inst, 2018, 110(4): 354-361.
|
| 2 |
Eikenboom EL, van Doorn HC, Dinjens WNM, et al. Gynecological surveillance and surgery outcomes in Dutch lynch syndrome carriers[J]. Cancers, 2021, 13(3): 459.
|
| 3 |
Gordhandas S, Kahn RM, Gamble C, et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency[J]. Ecancermedicalscience, 2020, 14: 1061.
|
| 4 |
Buchanan DD, Tan YY, Walsh MD, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing[J]. J Clin Oncol, 2014, 32(2): 90-100.
|
| 5 |
Hampel H, Pearlman R, de la Chapelle A, et al. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients[J]. Gynecol Oncol, 2021, 160(1): 161-168.
|
| 6 |
Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology, 2010, 56(2): 167-179.
|
| 7 |
Zhang H,Richards B,Wilson T,et al. Apoptosis induced by overexpression of hMSH2 or hMLH1[J].Cancer Res,1999,59(13):3021-3027.
|
| 8 |
Cerretelli G, Ager A, Arends MJ, et al. Molecular pathology of Lynch syndrome[J]. J Pathol, 2020, 250(5): 518-531.
|
| 9 |
ACOG Practice bulletin no. 147[J]. Obstet Gynecol, 2014, 124(5): 1042-1054.
|
| 10 |
Carvalho JP, Del Giglio A, Achatz MI, et al. Complete clinical response in stage IVB endometrioid endometrial carcinoma after first-line pembrolizumab therapy: report of a case with isolated loss of PMS2 protein[J]. Case Rep Oncol, 2020, 13(3): 1067-1074.
|
| 11 |
Mas-Moya J, Dudley B, Brand RE, et al. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome[J]. Hum Pathol, 2015, 46(11): 1616-1625.
|
| 12 |
Chika N, Eguchi H, Kumamoto K, et al. Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population[J]. Jpn J Clin Oncol, 2017, 47(2): 191.
|
| 13 |
Zhang K, Liu Y, Liu X, et al. Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas[J]. Pathology, 2021, 53(2): 179-186.
|
| 14 |
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447): 67-73.
|
| 15 |
Ono R, Nakayama K, Nakamura K, et al. Dedifferentiated endometrial carcinoma could be A target for immune checkpoint inhibitors (anti PD-1/PD-L1 antibodies)[J]. Int J Mol Sci, 2019, 20(15).
|
| 16 |
Conlon N, Da Cruz Paula A, Ashley CW, et al. Endometrial carcinomas with a ̒ ̒serous'' component in young women are enriched for DNA mismatch repair deficiency, lynch syndrome, and POLE exonuclease domain mutations[J]. Am J Surg Pathol, 2020, 44(5): 641-648.
|
| 17 |
Pasanen A, Loukovaara M, Bützow R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma[J]. Mod Pathol, 2020, 33(7): 1443-1452.
|
| 18 |
Doulgeraki T,Vagios S,Kavoura E,et al. Mismatch repair status in high-grade endometrial carcinomas of endimetrioid and non-endometrioid type[J].J BUON,2019,24(5):2020-2027.
|
| 19 |
Kim SR, Tone A, Kim RH, et al. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study[J]. Gynecol Oncol, 2021, 161(1): 221-227.
|
| 20 |
Maby P, Tougeron D, Hamieh M, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy[J]. Cancer Res, 2015, 75(17): 3446-3455.
|
| 21 |
Clendenning M, Huang A, Jayasekara H, et al. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas[J]. Fam Cancer, 2018, 17(1): 91-100.
|
| 22 |
Seth S, Ager A, Arends MJ, et al. Lynch syndrome-cancer pathways, heterogeneity and immune escape[J]. J Pathol, 2018, 246(2): 129-133.
|
| 23 |
Mariya T, Kubo T, Hirohashi Y, et al. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer[J]. Med Mol Morphol, 2021, 54(1): 14-22.
|
| 24 |
Bohaumilitzky L, von Knebel Doeberitz M, Kloor M, et al. Implications of hereditary origin on the immune phenotype of mismatch repair-deficient cancers: systematic literature review[J]. J Clin Med, 2020, 9(6): 1741.
|
| 25 |
Ramchander NC, Ryan NAJ, Walker TDJ, et al. Distinct immunological landscapes characterize inherited and sporadic mismatch repair deficient endometrial cancer[J]. Front Immunol, 2019, 10: 3023.
|
| 26 |
Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer[J]. Gynecol Oncol, 2019, 154(1): 124-130.
|
| 27 |
León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy[J]. J Clin Oncol, 2020, 38(29): 3388-3397.
|
| 28 |
Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1[J]. JAMA Oncol, 2015, 1(9): 1319-1323.
|
| 29 |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| 30 |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.
|
| 31 |
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10.
|
| 32 |
Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(5): 711-718.
|
| 33 |
Ramos A, Fortin SAM, Melchert V, et al. Checkpoint inhibitor signatures across endometrial carcinoma histologic subtypes[J]. Gynecol Oncol, 2018, 149(3): 621.
|
| 34 |
Sloan EA, Ring KL, Willis BC, et al. PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors[J]. Am J Surg Pathol, 2017, 41(3): 326-333.
|
), 滕银成(
